Diphenhydramine and Aluminium MgS

Phase 2Small molecule

Diphenhydramine and Aluminium MgS is one of 6 small molecule programs targeting Recurrent aphthous stomatitis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Recurrent Aphthous StomatitisActive, not recruiting

Recurrent Aphthous StomatitisPhase 2

Active, not recruiting

Competition

Competitive Landscape

13 competitors in Recurrent Aphthous Stomatitis

#DrugCompanyPhaseTrials

Kenalog

BBausch Health Americas, Inc.

Otezla

1 3

Omega 3

MMassachusetts General Hospital

Phase 2

1 4

Use Concentrated Growth Factor.

TTanta University

Phase 2

1 5

Trental

VValidus Pharmaceuticals

Preclinical

1 6

Diphenhydramine and Aluminium MgS

QQazvin University Of Medical Sciences

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Recurrent aphthous stomatitis1 trial

Therapeutic Effects of "Ibuprofen, Diphenhydramine and Aluminium MgS" on Recurrent Aphthous Stomatitis

Completed·QQazvin University Of Medical Sciences·Phase 2·NCT01293968·37 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Diphenhydramine and Aluminium MgS. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Diphenhydramine and Aluminium MgS compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Diphenhydramine and Aluminium MgS. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Qazvin University Of Medical Sciences company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: QQazvin University Of Medical Sciences

Diphenhydramine and Aluminium MgS

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Recurrent aphthous stomatitis1 trial

References

Drug Info

Quick Facts

Related News